Abstract:Estrogen receptor positive (ER+) breast cancer (BCa) accounts for the highest proportion of breast cancer-related deaths. While endocrine therapy is highly effective for this subpopulation, endocrine resistance remains a major challenge and the identification of novel targets is urgently needed. Previously, we have shown that Semaphorin 3C (SEMA3C) is an autocrine growth factor that drives the growth and treatment resistance of various cancers, but its role in breast cancer progression and endocrine resistance is poorly understood. Here, we report that SEMA3C plays a role in maintaining the growth of ER+ BCa cells and is a novel, tractable therapeutic target for the treatment of ER+ BCa patients. Analyses of publicly available clinical datasets indicate that ER+ BCa patients express significantly higher levels of SEMA3C mRNA than other subtypes. Furthermore, SEMA3C mRNA expression was positively correlated with ESR1 mRNA expression. ER+ BCa cell lines (MCF7 and T47D) expressed higher levels of SEMA3C mRNA and protein than a normal mammary epithelial MCF10A cell line. ER siRNA knockdown was suppressed, while dose-dependent beta-estradiol treatment induced SEMA3C expression in both MCF7 and T47D cells, suggesting that SEMA3C is an ER-regulated gene. The stimulation of ER+ BCa cells with recombinant SEMA3C activated MAPK and AKT signaling in a dose-dependent manner. Conversely, SEMA3C silencing inhibited Estrogen Receptor (ER) expression, MAPK and AKT signaling pathways while simultaneously inducing apoptosis, as monitored by flow cytometry and Western blot analyses. SEMA3C silencing significantly inhibited the growth of ER+ BCa cells, implicating a growth dependency of ER+ BCa cells on SEMA3C. Moreover, the analysis of tamoxifen resistant (TamR) cell models (TamC3 and TamR3) showed that SEMA3C levels remain high despite treatment with tamoxifen. Tamoxifen-resistant cells remained dependent on SEMA3C for growth and survival. Treatment with B1SP Fc fusion protein, a SEMA3C pathway inhibitor, attenuated SEMA3C-induced signaling and growth across a panel of tamoxifen sensitive and resistant ER+ breast cancer cells. Furthermore, SEMA3C silencing and B1SP treatment were associated with decreased EGFR signaling in TamR cells. Here, our study implicates SEMA3C in a functional role in ER+ breast cancer signaling and growth that suggests ER+ BCa patients may benefit from SEMA3C-targeted therapy.

SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint that Enables Tumor Immune Evasion by Impairing T Cell Cytotoxicity.

Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis.

Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells

Ncrnas-Mediated High Expression of SEMA3F Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma

Semaphorin3F down-regulates the expression of integrin α vβ3 and sensitizes multicellular tumor spheroids to chemotherapy via the neuropilin-2 receptor in vitro

SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment

Semaphorins as Potential Immune Therapeutic Targets for Cancer

SEMA3G Functions As a Novel Prognostic Biomarker Associated with Wnt Pathway in Clear Cell Renal Cell Carcinoma.

Systemic and Targeted Delivery of Semaphorin 3A Inhibits Tumor Angiogenesis and Progression in Mouse Tumor Models.

SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis

Semaphorin-3F is an Immune Suppressor, not a Tumor Suppressor, in Oral Carcinogenesis

Dependency of Tamoxifen Sensitive and Resistant ER+ Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth

Semaphorins in tumor microenvironment: Biological mechanisms and therapeutic progress

SEMA3F Prevents Metastasis of Colorectal Cancer by PI3K–AKT‐dependent Down‐regulation of the ASCL2–CXCR4 Axis

Novel Role of Semaphorin 3A in the Growth and Progression of Hepatocellular Carcinoma.

DDRE-15. Sema3C SIGNALING CONFERS RESISTANCE TO Wnt INHIBITION IN GLIOBLASTOMA

Semaphorin 3F Induces Colorectal Cancer Cell Chemosensitivity by Promoting P27 Nuclear Export

SEMA4b Inhibits MMP9 to Prevent Metastasis of Non-Small Cell Lung Cancer

Epigenetically Downregulated Semaphorin 3E Contributes to Gastric Cancer.

Research Progress on SEMA3B and Related Signal Pathways of Ionizing Radiation